Trevena resubmits a new drug application for its experimental opioid

Trevena Inc. said Monday it has resubmitted its new drug application for IV oliceridine, an opioid pain relief medicine designed to have fewer side affects than traditional opioids, to the Food and Drug Administration. The FDA in late 2018 rejected the Chester County biopharmaceutical company's application for oliceridine, which has the proposed brand name Olinvo, as a treatment for moderate-to-severe pain for patients while they are in the hospital. Trevena (NASDAQ: TRVN) conducted additional…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news